Fujikawa, Y.; Fukuo, Y.; Nishimura, K.; Tsujino, K.; Kashiwagi, H.; Hiramatsu, R.; Nonoguchi, N.; Furuse, M.; Takami, T.; Hu, N.; Miyatake, S.-I.; Takata, T.; Tanaka, H.; Watanabe, T.; Suzuki, M.; Kawabata, S.; Nakamura, H.; Wanibuchi, M. Evaluation of the Effectiveness of Boron Neutron Capture Therapy with Iodophenyl-Conjugated closo-Dodecaborate on a Rat Brain Tumor Model. Biology2023, 12, 1240.
Fujikawa, Y.; Fukuo, Y.; Nishimura, K.; Tsujino, K.; Kashiwagi, H.; Hiramatsu, R.; Nonoguchi, N.; Furuse, M.; Takami, T.; Hu, N.; Miyatake, S.-I.; Takata, T.; Tanaka, H.; Watanabe, T.; Suzuki, M.; Kawabata, S.; Nakamura, H.; Wanibuchi, M. Evaluation of the Effectiveness of Boron Neutron Capture Therapy with Iodophenyl-Conjugated closo-Dodecaborate on a Rat Brain Tumor Model. Biology 2023, 12, 1240.
Fujikawa, Y.; Fukuo, Y.; Nishimura, K.; Tsujino, K.; Kashiwagi, H.; Hiramatsu, R.; Nonoguchi, N.; Furuse, M.; Takami, T.; Hu, N.; Miyatake, S.-I.; Takata, T.; Tanaka, H.; Watanabe, T.; Suzuki, M.; Kawabata, S.; Nakamura, H.; Wanibuchi, M. Evaluation of the Effectiveness of Boron Neutron Capture Therapy with Iodophenyl-Conjugated closo-Dodecaborate on a Rat Brain Tumor Model. Biology2023, 12, 1240.
Fujikawa, Y.; Fukuo, Y.; Nishimura, K.; Tsujino, K.; Kashiwagi, H.; Hiramatsu, R.; Nonoguchi, N.; Furuse, M.; Takami, T.; Hu, N.; Miyatake, S.-I.; Takata, T.; Tanaka, H.; Watanabe, T.; Suzuki, M.; Kawabata, S.; Nakamura, H.; Wanibuchi, M. Evaluation of the Effectiveness of Boron Neutron Capture Therapy with Iodophenyl-Conjugated closo-Dodecaborate on a Rat Brain Tumor Model. Biology 2023, 12, 1240.
Abstract
High-grade gliomas present a significant challenge in neuro-oncology because of their aggressive nature and resistance to current therapies. Boron neutron capture therapy (BNCT) is a potential treatment method; however, the boron carrier compounds used — such as 4-borono-L-phenylalanine (L-BPA) — have limitations. This study evaluated the use of boron-conjugated 4-iodophenylbutanamide (BC-IP), a novel boron compound in BNCT, for the treatment of glioma. Using in vitro drug exposure experiments and in vivo studies, we compared BC-IP and BPA, with a focus on boron uptake and retention characteristics. The results showed that although BC-IP had a lower boron uptake than BPA, it exhibited superior retention. Furthermore, despite lower boron accumulation in tumors, BC-IP showed significant survival improvement in glioma-bearing rats compared to controls. These results suggest that BC-IP, with its unique properties, may be an alternative boron carrier for BNCT. Further research is required to optimize this potential treatment modality, which could significantly contribute to advancing the treatment of high-grade gliomas.
Biology and Life Sciences, Biology and Biotechnology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.